Safety and Efficacy of (+)-Epicatechin in Subjects with Friedreich's Ataxia: A Phase II, Open-Label, Prospective Study

Qureshi, M. Y., Patterson, M. C., Clark, V., Johnson, J. N., Moutvic, M. A., Driscoll, S. W., Kemppainen, J. L., Huston, J., 3rd, Anderson, J. R., Badley, A. D., Tebben, P. J., Wackel, P., Oglesbee, D., Glockner, J., Schreiner, G., Dugar, S., Touchette, J. C., & Gavrilova, R. H. (2020). Journal of inherited metabolic disease, 10.1002/jimd.12285. Advance online publication. doi:10.1002/jimd.12285


(+)-EPI was well tolerated over 24 weeks at up to 150 mg/day. Improvement was observed in cardiac structure and function in subset of subjects with FRDA without statistically significant improvement in primary neurological outcomes.


Safety and Efficacy of (+)-Epicatechin in Subjects with Friedreich's Ataxia: A Phase II, Open-Label, Prospective Study